Latest Conference Articles

At AAO 2022 in Chicago, Illinios, Christopher Starr, MD, presented a talk entitled, "Efficacy of OC-01 (varenicline solution) (VNS) 0.03mg for Treatment of Dry Eye Disease Signs and Symptoms in Subjects With and Without Antidepressant/ Anxiolytic Use: Post-hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials."

Janssen noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.

The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.

In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Ines Lains, MD, PhD, detailed how adjunct treatment with intravitreal antivirals or early pars plana vitrectomy did not improve the rates of retinal detachment in patients diagnosed with acute retinal necrosis.

The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.

The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.

The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.

First-in-human biologic stent in ophthalmology is a conforming implant material, i.e., a soft, scleral wall compliant bio-tissue to structurally reinforce the cyclodialysis cleft opening.

Robot-assisted surgical precision offers less than 5-µm precision tremor stabilization, 1 to 10-mN force-sensing smart instrumentation and automated procedure-specific guidance and assistance with analytics.

Mark H. Blecher, MD, dives into his AAO 2022 topic: "One-Year Visual Outcomes Following Monocular Implantation with a Small Aperture IOL."

In a poster presented at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Yu-Yen Chen, MD, PhD, noted that patients diagnosed with normal-tension glaucoma (NTG) have a significantly higher risk of developing Alzheimer’s disease compared with those without NTG.

At the 2022 American Academy of Ophthalmology meeting, Justis Ehlers, MD, presented a talk titled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

At AAO 2022, Dr Justis Ehlers presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

At AAO 2022, Justis Ehlers, MD, presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

Novel glasses, designed for children with cranial dysotosis, help doctors provide functional eyewear for children in underserved communities, says Donny Suh, MD.

David Hutton discusses the AAO 2022 talk, "Corneal Oedema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with presenter Dr Francis S. Mah.

David Hutton discusses the AAO 2022 presentation, "Corneal Edema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with speaker Francis S. Mah, MD.

Almost 5 million patients in the IRIS Registry had received at least one diagnosis of DED between 2013 and 2019; of those, 203,171 were children under 18 years of age and 4,592,808 were adults.

During a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Vivian Paraskevi Douglas, MD, DVM, MBA, MSc, detailed a study in which investigators used the extensive data in the American Academy of Ophthalmology IRIS Registry to study the difference between the pediatric and adult populations.

During a presentation at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago, Maria A. Guzman Aparicio, MD, and Teresa C. Chen, MD, detailed their research that found that pediatric patients have a significantly higher incidence of new-onset strabismus after tube shunt surgery for glaucoma compared with adults.

Almost 5 million patients in the IRIS Registry had received at least one diagnosis of DED between 2013 and 2019; of those, 203,171 were children under 18 years of age and 4,592,808 were adults.

Data were presented during an oral presentation at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago.

Investigators reported that the safety and efficacy of the Tecnis Synergy IOL model ZFR00V indicates that it may be a good option for patients who desire meaningful gains in uncorrected visual acuity at all distances.

Academic leaders will review their experience with the technology during a symposium at the American Academy of Ophthalmology annual meeting, being held at McCormick Place in Chicago.

During the American Academy of Ophthalmology 2022 Annual Meeting in Chicago,Tarsus Pharmaceuticals Inc. announced the launch of the “Look at the Lids” disease education campaign for Demodex blepharitis.

13% of pediatric patients had new-onset strabismus after a tube shunt procedure; in contrast, 0% of adults had new-onset strabismus after tube shunt surgery (at 6 months or at last follow-up).

Mark Packer, MD, speaks on his 2022 AAO poster: "Safety and Effectiveness of a New FDA-Approved Dispersive Ophthalmic Viscosurgical Device."

Ben Bergo, CEO of Visus Therapeutics, announced the acquisition of all patents and other assets of ViewPoint Therapeutics, which will accelerate development of novel alpha-crystallin chaperone compounds as a non-surgical treatment for age-related cataracts.